skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [1];  [3];  [1];  [3];  [2];  [1];  [3]
  1. Department of Clinical Oncology, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong (China)
  2. Department of Radiation Oncology, Cancer Center and State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou (China)
  3. Department of Nasopharyngeal Carcinoma, Cancer Center and State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou (China)

Purpose: Induction chemotherapy has not been shown to improve survival in nasopharyngeal carcinoma (NPC) in Phase III trials. To evaluate the effect of induction chemotherapy in NPC further, we performed subgroup analysis of two Phase III trials according to the T and N stage. Methods and Materials: Data from two phase III trials comparing cisplatin/epirubicin or cisplatin/bleomycin/5-fluorouracil followed by radiotherapy (RT) vs. RT alone in NPC were pooled together for analysis. Patients were stratified into four subgroups according to the 1997 American Joint Committee on Cancer T and N stage: T1-T2N0-N1, Group 1 (early-stage disease); T1-T2N2-N3, Group 2 (advanced N disease); T3-T4N0-N1, Group 3 (advanced T stage); and T3-T4N2-N3, Group 4 (advanced T and N disease). Group 1 consisted entirely of patients with Stage IIB disease. A total of 784 patients were included for analysis on an intent-to-treat basis. The median follow-up for the surviving patients was 67 months. Results: No significant differences in overall survival, locoregional failure-free, or distant metastasis-free rates were observed between the combined and RT arms in Groups 2 to 4. Significant differences in the overall survival and distant metastasis-free rates were observed only in Group 1, favoring the combined chemotherapy and RT arm. The 5-year overall survival rate was 79% in the combined arm and 67% in the RT-alone arm (p 0.048). The corresponding 5-year distant metastasis-free rates were 86% and 74% (p = 0.0053). Conclusions: Our results have shown that patients in Group 1, with early-stage NPC treated by RT alone, had relatively poor survival because of distant metastases. The observation of improved outcomes in this subgroup after the addition of induction chemotherapy has not been previously reported and warrants additional investigation.

OSTI ID:
20850007
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 65, Issue 5; Other Information: DOI: 10.1016/j.ijrobp.2006.02.016; PII: S0360-3016(06)00374-9; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma
Journal Article · Wed Feb 01 00:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20850007

Hypofractionated Dose-Painting Intensity Modulated Radiation Therapy With Chemotherapy for Nasopharyngeal Carcinoma: A Prospective Trial
Journal Article · Sun May 01 00:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20850007

High-Sensitivity C-Reactive Protein Complements Plasma Epstein-Barr Virus Deoxyribonucleic Acid Prognostication in Nasopharyngeal Carcinoma: A Large-Scale Retrospective and Prospective Cohort Study
Journal Article · Sun Feb 01 00:00:00 EST 2015 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20850007